Maintenance Fruquintinib Plus Capecitabine Is Active, Tolerable in RAS/BRAF Wild-Type mCRC
Fruquintinib plus capecitabine demonstrated preliminary efficacy and safety as maintenance therapy in RAS/BRAF wild-type metastatic colorectal cancer.
Related Articles
The fit older adult with acute myeloid leukemia: clinical challenges to providing evidence-based frontline treatment
Recent molecular and diagnostic advances in acute myeloid leukemia (AML) have led investigators and clinicians to further categorize patients in different
ASH Clinical Research Training Institute in Latin America
The Clinical Research Training Institute in Latin America is intended for fellows and early to mid-career hematology faculty working in Latin American countries who are…
MAIC Analysis Shows PFS Favorability With Zanubrutinib vs Acalabrutinib/Venetoclax in CLL
A matching-adjusted indirect comparison of zanubrutinib and acalabrutinib/venetoclax showed favorability towards zanubrutinib in patients with CLL.
Isa-KRd Yields Prolonged MRD Negativity vs KRd in Newly Diagnosed Myeloma
Isa-KRd significantly improved the 1-year MRD negativity rate compared with KRd alone in newly diagnosed patients with multiple myeloma.
Elranatamab Triplet Yields Nearly 100% ORR in Newly Diagnosed Multiple Myeloma
Results from dose level G of MagnetisMM-6 found high response rates with an elranatamab triplet in patients with newly diagnosed multiple myeloma.
SurgOnc Today® – Society of Surgical Oncology
SurgOnc Today® is an educational podcast for cancer surgeons from the Society of Surgical Oncology. Each episode features conversations with individuals who are experts within their…
Uterine/Endometrial Cancer/GTD | Foundation For Women’s Cancer
This section will take you through the basics of what you need to know about endometrial cancer. It will introduce you to the people who…
FDA Grants Orphan Drug Designation to CID-078 for SCLC
The FDA has granted orphan drug designation to CID-078 for the treatment of patients with small cell lung cancer.
Digital PATH Project – Friends of Cancer Research
Digital and Computational Pathology Tool Harmonization Project Quick Links Sign Up for Updates September 2023 White Paper Digital Pathology One Pager Project Outcomes The Digital…
Liso-Cel Yields Durable Responses in R/R Marginal Zone Lymphoma
Liso-cel generated deep and durable responses in relapsed/refractory marginal zone lymphoma.